Table: Nxera Pharma -Q1 group results (IFRS)

Nxera Pharma

02/05/2025 07:30

May 2 (Reuters)- 
              Nxera Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   3 months ended      3 months ended       Year to 
                  Mar 31, 2025        Mar 31, 2024     Dec 31, 2025 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales               6.64                4.61                      
                   (+44.1 pct)        (+389.0 pct)                  
  Operating         loss 2.19           loss 3.08                   
  Pretax            loss 2.16           loss 2.80                   
  Net             loss 760 mln          loss 3.28                   
  EPS Basic       loss 8.45 yen      loss 36.68 yen                 
  EPS Diluted     loss 8.45 yen      loss 36.68 yen                 
  Ann Div                                  NIL              NIL     
  -Q2 Div                                  NIL              NIL     
  -Q4 Div                                  NIL              NIL     
 
  NOTE - Nxera Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4565.T